 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that the U.S. Food and Drug Administration FDA has notified the Company in a letter that it has placed a clinical hold on the proposed Phase 2 clinical trial of KVD824. KVD824 is KalVistas oral product candidate being developed for proph 